Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details)

v2.4.0.8
Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details) (USD $)
Jun. 30, 2014
Dec. 31, 2013
Mar. 31, 2013
OPKO Renal
Mar. 31, 2013
OPKO Renal
Patents
Mar. 31, 2013
OPKO Renal
In process research and development
Aug. 31, 2013
OPKO Biologics
Aug. 31, 2013
OPKO Biologics
Patents
Aug. 31, 2013
OPKO Biologics
In process research and development
Business Acquisition [Line Items]                
Current assets     $ 1,224,000 [1]     $ 21,500,000 [1]    
Intangible assets:                
In-process research and development         191,530,000     590,200,000
Patents       210,000     0  
Total intangible assets     191,740,000     590,200,000    
Goodwill 226,001,000 [2] 226,373,000 [2] 2,411,000     139,784,000    
Property, plant and equipment     306,000     1,057,000    
Other assets     0     371,000    
Accounts payable and accrued expenses     (1,069,000)     (9,866,000)    
Deferred tax liability     0     (156,403,000)    
Total purchase price     194,612,000     586,643,000    
Current Asset include cash     $ 400,000     $ 20,500,000    
[1] Current assets include cash of $0.4 million and $20.5 million related to the OPKO Renal and OPKO Biologics acquisitions, respectively
[2] As of June 30, 2014 and December 31, 2013, total assets include $7.7 million and $6.7 million, respectively, and total liabilities include $13.5 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.